Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FDEL5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $17,021.36 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 capsules of Xtandi 40 mg. The delivery order, issued on December 1, 2025, with an ultimate completion date of December 2, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This award was made without subcontractor involvement and represents a routine pharmaceutical supply transaction typical of DLA's ongoing medical procurement operations.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a $500 million ceiling and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor for pharmaceutical products supporting Department of Defense military healthcare facilities worldwide. Xtandi, an oncology treatment within the vendor's comprehensive pharmaceutical portfolio, exemplifies the specialized pharmaceutical requirements that this indefinite delivery contract framework enables DLA to fulfill efficiently across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FDEL5?
SPE2DR26FDEL5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FDEL5 worth?
The government has obligated $17,021 on SPE2DR26FDEL5.
Is contract SPE2DR26FDEL5 an order under another contract?
Yes. SPE2DR26FDEL5 is a delivery order under SPE2DR25D9112, an indefinite delivery contract.
Was contract SPE2DR26FDEL5 competed?
The extent of competition for SPE2DR26FDEL5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award